Stryker Corporation vs Veritone Inc — how do they compare? Stryker Corporation trades at $277.33 (market cap $106.24B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: Stryker Corporation is far larger — about 1786.7× Veritone Inc's market cap, and Stryker Corporation pays a 1.27% dividend while Veritone Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and Veritone Inc for 12 Days on average.
| SYK | VERI | |
|---|---|---|
Market Cap | $106.24B | $59.46M |
Volume | 2,982,001 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $388.35 | $8.39 |
52-Week Low | $269.75 | $0.56 |
Typical Hold Time | 21 Days | 12 Days |
Enterprise Value | $117.70B | $94.86M |
Dividend Yield | 1.27% | — |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Veritone (VERI) trades at $0.5851, down 15.36% in the past 24 hours, reflecting significant bearish pressure. The company shows concerning fundamentals with a net income margin of -117.54% and negative ROE of -547.67% for 2025, though it maintains a gross margin of 66.2%. Recent developments include a $15 million equity offering and partnerships with ATP Media and ZeroEyes, while facing securities class action investigations. Technical indicators show mixed signals with bearish moving averages but bullish oscillators.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests upside potential with a $3.75 price target. Key risks include ongoing legal scrutiny, execution challenges in achieving profitability, and competitive pressures in the AI solutions space. The stock presents high-risk speculative potential for investors betting on turnaround execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →